Saturday, 25 May 2024

Australia's most trusted
source of pharma news

Saturday, 25 May 2024
Listen to this story 

Long-term data buffers Wegovy

Posted 15 May 2024 AM

New data from the largest and longest clinical trial of semaglutide on weight loss have affirmed the longevity and safety of the drug over four years.

The data from the 17,000 person Semaglutide and Cardiovascular Outcomes (SELECT) trial, presented at the European Congress on Obesity this week, showed that people taking semaglutide lost on average 10.2 per cent of their body weight and 7.7 cm from their waistline, compared with 1.5 per cent of weight and 1.3 cm of waistline for the placebo group.

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (20)

Clinical & Medical, R&D (10)

Regulatory, Pharmacovigilance & QA (6)

Other (32)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.